智專奧米加

健康優質的奧米加-3

立即購買

健康的來源來自愛力思智專奧米加

Allysian 愛力思智專奧米加™ 是由純 Neptune Krill Oil® 提煉而成的磷蝦油，這產品含有優質的生物可用性並具有抗氧化劑功效的奧米加。在磷蝦油中的 EPA 和 DHA 附帶磷脂,這相對於魚油中的奧米加脂肪酸中附帶的甘油三脂。其實 NKO 跟魚油是不同的，它既是純脂溶性也比較容易消化。這 NKO 磷脂油的構造同時包含脂溶性及水溶性的成份，這 NKO 中的奧米加 3 比在魚油中的奧米加含量多出 2.5 倍。舉例來說，1000 毫克的奧米加已經相當於 2500 毫克的魚油攝取量。該專利得出的結果顯示能有效地增強生物活性，它相比魚油它能更進一步提高消化率，吸收和功效。 NKO 中含有的蝦青素抗氧化劑比其他的磷蝦油高出 7 倍以上。這個強勁的抗氧化劑提供優質的保護來對抗氧化劑，大大提高了產品的使用時間.亦同時傳遞了身體健康的額外益處。 作為抗氧化劑,它亦具有助身體保護自己免受自由基影響的能力。

立即購買

智專奧米加™ 採用的磷虾油和白藜蘆醇具有廣
泛的效益，其中包括

  • Omega-3 脂肪酸 (EPA和DHA)，可保持身體良好狀態
  • 生物活性比一般魚油高2.5倍*1,2
  • 蝦青素(超强抗氧化劑)，含量比其他磷虾油多7倍*
  • 具有抗氧化和抗炎功能，可支持心臟功能健康*
  • 專利提煉方法
  • 確保產品純度和安全性

  • 可持續性

    Friend of the Sea “海洋之友” 認証

  • 易於吞嚥

    細小光滑軟膠囊

  • 食用後無魚腥味

    顏色來自海草

磷蝦油參考文獻:

  1. Berge, R. K., Ramsvik, M. S., Bohov, P., Svardal, A., Nordrehaug, J. E., Rostrup, E., ... & Bjørndal, B. (2015). Krill oil reduces plasma triacylglycerol level and improves related lipoprotein particle concentration, fatty acid composition and redox status in healthy young adults-a pilot study. Lipids in health and disease, 14(1), 1.
  2. Ramprasath, V. R., Eyal, I., Zchut, S., Shafat, I., & Jones, P. J. H. (2015). Supplementation of krill oil with high phospholipid content increases sum of EPA and DHA in erythrocytes compared with low phospholipid krill oil. Lipids in health and disease, 14(1), 1.

100%純磷虾油®

天然成分:

  • 脂肪酸（EPA & DHA)

    omega-3 脂肪酸，支持心血管系統，有效促進大腦，眼睛和精神元發展。*1-22

  • 磷脂質

    奧米加™ 磷蝦油富含磷脂質, 包含可溶解脂肪和融水性的脂肪酸，可有效將營養輸送入細胞膜。因此吸收速度比普通魚油快2.5倍多。*23-30

  • 蝦青素

    在磷蝦中天然含有的關鍵類胡蘿蔔素, 使其外殼成粉紅色，來源於其食用的微藻類。蝦青素強有效的抗氧化力可保護人體組織避免氧化損害。用於心血管疾病，免疫系統，消炎，神經變性疾病。*31-39

白藜蘆醇

白藜蘆醇可有效抗老化，有助於心血管健康，抵抗癌症，和神經保護功能。*40-54

脂肪酸（EPA & DHA):

  1. "FDA announces qualified health claims for omega-3 fatty acids" (Press release). United States Food and Drug Administration. September 8, 2004. Retrieved 2006-07-10.
  2. Canadian Food Inspection Agency. Acceptable nutrient function claims. Accessed 30 April 2015
  3. “Fish, Levels of Mercury and Omega-3 Fatty Acids". American Heart Association. Retrieved October 6,2010.
  4. Kris-Etherton, P. M., Harris, W. S., Appel, L. J., & Nutrition Committee. (2002). Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. circulation, 106(21), 2747-2757.
  5. Gruenwald, J., Petzold, E., Busch, R., Petzold, H.P., & Graubaum, H.J. (2009). Effect of glucosamine sulfate with or without omega-3 fatty acids in patients with osteoarthritis. Adv Ther, 26(9), 838-871.
  6. Goldberg, R.J., & Katz, J. (2007). A meta-analysis of the analgesic effects of omega-3 polyunsaturated fatty acid supplementation for inflammatory joint pain. Pain, 129(1-2), 210-223.
  7. Hill, C.L., March, L.M., Aitken, D., Lester, S.E., Battersby, R., Hynes, K., et al. (2015). Fish oil in knee osteoarthritis: a randomised clinical trial of low dose versus high dose. Ann Rheum Dis, 75(1), 23-29.
  8. Maroon, J.C., & Bost, J.W. (2006). Omega-3 fatty acids (fish oil) as an anti-inflammatory: an alternative to nonsteroidal anti-inflammatory drugs for discogenic pain. Surg Neurol, 65(4), 326-331.
  9. Bhargava, R., Kumar, P., Kumar, M., Mehra, N., & Mishra, A. (2013). A randomized controlled trial of omega-3 fatty acids in dry eye syndrome. Int J Ophthalmol, 6(6), 811-816.
  10. Deinema, L.A., Vingrys, A.J., Wong, C.Y., Jackson, D.C., Chinnery, H.R., & Downie, L.E. (2017). A randomized, double-masked, placebo-controlled clinical trial of two forms of omega-3 supplements for treating dry eye disease. Ophthalmology, 124(1), 43-52.
  11. Mohammadpour, M., Mehrabi, S., Hassanpoor, N., & Mirshahi, R. (2017). Effects of adjuvant omega-3 fatty acid supplementation on dry eye syndrome following cataract surgery: a randomized clinical trial. Journal of Current Ophthalmology, 29(1), 33-38.
  12. Balk, E., Chung, M., Lichtenstein, A., Chew, P., Kupelnick, B., Lawrence, A., et al. (2004). Effects of omega-3 fatty acids on cardiovascular risk factors and intermediate markers of cardiovascular disease: summary, evidence report/technology assessment no.93. AHRQ Publication No. 04-E010-1. Rockville (MD): Agency for Healthcare Research and Quality.
  13. EFSA 2012: European Food Safety Authority. Scientific opinion: scientific opinion on the tolerable upper intake level of eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) and docosapentaenoic acid (DPA). EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA). EFSA Journal 2012, 10(7):2815.
  14. Hooper, L., Thompson, R.L., Harrison, R.A., Summerbell, C.D., Moore, H., Worthington, H.V., et al. (2004). Omega 3 fatty acids for prevention and treatment of cardiovascular disease. Cochrane Database of Systematic Reviews (4):CD003177.
  15. Kris-Etherton, P.M., Harris, W.S., & Appell, L.I. (2002). Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation, 106(21), 2747-2757.
  16. Leaf, A., Kang, J.X., Xiao, Y.F., & Billman, G.E. (2003). Clinical prevention of sudden cardiac death by n-3 polyunsaturated fatty acids and mechanism of prevention of arrhythmias by n-3 fish oils. Circulation, 107(21), 2646-2652.
  17. Nilsen, D.W., Albrektsen, G., Landmark, K., Moen, S., Aarsland, T., & Woie, L. (2001). Effects of a high-dose concentrate of n-3 fatty acids or corn oil introduced early after an acute myocardial infarction on serum triacylglycerol and HDL cholesterol. The American Journal of Clinical Nutritio,n 74(1):50-56.
  18. Oh, R. (2005). Practical applications of fish oil (Ω-3 fatty acids) in primary care. The Journal Of The American Board Of Family Practice, 18(1):28-36.
  19. Sirtori, C.R., Crepaldi, G. Manzato, E., Mancini, M., Rivellese, A., Paoletti, R., et al. (1998). One-year treatment with ethyl esters of n-3 fatty acids in patients with hypertriglyceridemia and glucose intolerance: reduced triglyceridemia, total cholesterol and increased HDL-C without glycemic alterations. Atherosclerosis, 137(2):419-427.
  20. Calder, P.C. (2015). Marine omega-3 fatty acids and inflammatory processes: effects, mechanisms and clinical relevance. Biochim Biophys Acta, 1851(4), 469-484.
  21. Yan, Y., Jiang, W., Spinetti, T., Tardivel, A., Castillo, R., Bourquin, C., et al. (2013). Omega-3 fatty acids prevent inflammation and metabolic disorder through inhibition of NLRP3 inflammasome activation. Immunity, 38(6), 1154-1163.
  22. Yates, C.M., Calder, P.C., & Ed Rainger, G. (2014). Pharmacology and therapeutics of omega-3 polyunsaturated fatty acids in chronic inflammatory disease. Pharmacol Ther, 141(3), 272-282.

磷脂質:

  1. Burri, L., Hoem, N., Banni, S., & Berge, K. (2012). Marine omega-3 phospholipids: metabolism and biological activities. Int J Mol Sci, 13(11), 15401-15419.
  2. Ramprasath, V.R., Eyal, I., Zchut, S., & Jones, P.J. (2013). Enhanced increase of omega-3 index in healthy individuals with response to 4-week n-3 fatty acid supplementation from krill oil versus fish oil. Lipids Health Dis. doi: 10.1186/1476-511X-12-178.
  3. Schuchardt, J.P., Schneider, I., Meyer, H., Neubronner, J., von Schacky, C., & Hahn, A. (2011). Incorporation of EPA and DHA into plasma phospholipids in response to different omega-3 fatty acid formulations – a comparative bioavailability study of fish oil vs. krill oil. Lipids Health Dis. doi: 10.1186/1476-511X-10-145.
  4. Ramprasath, V. R., Eyal, I., Zchut, S., Shafat, I., & Jones, P. J. H. (2015). Supplementation of krill oil with high phospholipid content increases sum of EPA and DHA in erythrocytes compared with low phospholipid krill oil. Lipids in health and disease, 14(1), 1.
  5. Berge, R. K., Ramsvik, M. S., Bohov, P., Svardal, A., Nordrehaug, J. E., Rostrup, E., ... & Bjørndal, B. (2015). Krill oil reduces plasma triacylglycerol level and improves related lipoprotein particle concentration, fatty acid composition and redox status in healthy young adults-a pilot study. Lipids in health and disease, 14(1), 1.
  6. Ulven, S. M., & Holven, K. B. (2015). Comparison of bioavailability of krill oil versus fish oil and health effect. Vascular health and risk management, 11, 511.
  7. Küllenberg, D., Taylor, L. A., Schneider, M., & Massing, U. (2012). Health effects of dietary phospholipids. Lipids in health and disease, 11(1), 1.
  8. Clinical Study Report. NO. BTS 275/07. February 16, 2009. Esslingen, Germany

蝦青素:

  1. Ambati, R.R., Phang, S.M., Ravi, S., & Aswathanarayana, R.G. (2014). Astaxanthin: sources, extraction, stability, biological activities and its commercial applications – a review. Mar Drugs, 12, 128-152.
  2. Barros, M.P., Poppe, S.C., & Bondan, E.F. (2014). Neuroprotective properties of the marine carotenoid astaxanthin and omega-3 fatty acids, and perspectives for the natural combination of both in krill oil. Nutrients, 6(3), 1293-1317.
  3. Lu, F.S., Bruheim, I., Haugsgjerd, B.O., & Jacobsen, C. (2014). Effect of temperature towards lipid oxidation and non-enzymatic browning reactions in krill oil upon storage. Food Chem, 157, 398-407.
  4. Otton, R., Marin, D.P., Bolin, A.P., de Cassia Santos Macedo, R., Campoio, T.R., Fineto, C., et al. (2012). Combined fish oil and astaxanthin supplementation modulates rat lymphocyte function. Eur J Nutr, 51(6), 707-718.
  5. Saw, C.L., Yang, A.Y., Guo, Y., Kong, A.N. (2013). Astaxanthin and omega-3 fatty acids individually and in combination protect against oxidative stress via the Nrf2-ARE pathway. Food Chem Toxicol, 62, 869-975.
  6. Fassett, R. G., & Coombes, J. S. (2009). Astaxanthin, oxidative stress, inflammation and cardiovascular disease. Future Cardiology, 5(4), 333-342.
  7. Guerin, M., Huntley, M. E., & Olaizola, M. (2003). Haematococcus astaxanthin: applications for human health and nutrition. TRENDS in Biotechnology, 21(5), 210-216.
  8. Mortensen, A., & Skibsted, L. H. (1997). Importance of carotenoid structure in radical-scavenging reactions. Journal of Agricultural and Food Chemistry,45(8), 2970-2977.
  9. Lennikov, A., Kitaichi, N., Fukase, R., Murata, M., Noda, K., Ando, R., ... & Ishida, S. (2012). Amelioration of ultraviolet-induced photokeratitis in mice treated with astaxanthin eye drops.

白藜蘆醇參考文獻:

  1. Liu, Y., Ma, W., Zhang, P., He, S., & Huang, D. (2015). Effect of resveratrol on blood pressure: a meta-analysis of randomized controlled trials. Clinical Nutrition, 34(1), 27-34.
  2. Jang, M., Cai, L., Udeani, G. O., Slowing, K. V., Thomas, C. F., Beecher, C. W., ... & Moon, R. C. (1997). Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science, 275(5297), 218-220.
  3. Magyar, K., Halmosi, R., Palfi, A., Feher, G., Czopf, L., Fulop, A., ... & Szabados, E. (2012). Cardioprotection by resveratrol: A human clinical trial in patients with stable coronary artery disease. Clinical hemorheology and microcirculation, 50(3), 179-187.
  4. Kennedy, D. O., Wightman, E. L., Reay, J. L., Lietz, G., Okello, E. J., Wilde, A., & Haskell, C. F. (2010). Effects of resveratrol on cerebral blood flow variables and cognitive performance in humans: a double-blind, placebo-controlled, crossover investigation. The American journal of clinical nutrition,91(6), 1590-1597.
  5. Bo, S., Ciccone, G., Castiglione, A., Gambino, R., De Michieli, F., Villois, P., et al. (2013). Anti-inflammatory and antioxidant effects of resveratrol in healthy smokers a randomized, double-blind, placebo-controlled, cross-over trial. Curr Med Chem, 20(1), 1323-1331.
  6. Carrizzo, A., Forte, M., Damato, A., Trimarco, V., Salzano, F., Bartolo, M., et al. (2013). Antioxidant effects of resveratrol in cardiovascular, cerebral and metabolic disease. Food Chem Toxicol, 61, 215-226.
  7. Chan, C.M., Huang, C.H., Li, H.J., Hsiao, C.Y., Su, C.C., Lee, P.L., & Hung, C.F. (2015). Protective effects of resveratrol against UVA-induced damage in ARPE19 cells. Int J Mol Sci, 16(3), 5789-5802.
  8. Farris, P., Krutmann, J., Li, Y.H., McDaniel, D., & Krol, Y. (2013). Resveratrol: a unique antioxidant offering a multi-mechanistic approach for treating aging skin. J Drugs Dermatol, 12(12), 1389-1394.
  9. Gobec, M., Tomasic, T., Markovic, T., Mlinaric-Rascan, I., Dolenc, M.S., & Jakopin, Z. (2015). Antioxidant and anti-inflammatory properties of 1, 2, 4-oxadiazole analogs of resveratrol. Chem Biol Interact, 240, 200-207.
  10. He, S., & Yan, X. (2013). From resveratrol to its derivatives: new sources of natural antioxidant. Curr Med Chem, 20(8), 1005-1017.
  11. Ido, Y., Duranton, A., Lan, F., Weikel, K.A., Breton, L., & Ruderman, N.B. (2015). Resveratrol prevents oxidative stress-induced senescence and proliferative dysfunction by activating the AMPK-FOXO3 cascade in cultured primary human keratinocytes. PLoS One, 10(2), e0115341.
  12. Mamalis, A., Koo, E., & Jagdeo, J. (2016). Resveratrol prevents reactive oxygen species-induced effects of light-emitting diode-generated blue light in human skin fibroblasts. Dermatol Surg, 42(6), 727-732.
  13. Ndiaye, M., Philippe, C., Mukhtar, H., & Ahmad, N. (2011). The grape antioxidant resveratrol for skin disorders: promise, prospects, and challenges. Arch Biochem Biophys, 508(2), 164-170.
  14. Pangeni, r., Sahni, J.K., Ali, J., Sharma, S., & Baboota, S. (2014). Resveratrol: review on therapeutic potential and recent advances in drug delivery. Expert Opin Drug Deliv, 11(8), 1285-1298.
  15. Soeur, J., Eilstein, J., Lereaux, G., Jones, C., & Marrot, L. (2015). Skin resistance to oxidative stress induced by resveratrol: from Nrf2 activation to GSH biosynthesis. Free Radic Biol Med, 78, 213-223.

奧米加-3的來源- 每顆軟膠囊含500毫克的EPA 及 DHA。每天服用2顆（請隨餐服用)。

  • 瓶裝: 60 膠囊
  • 每份重量: 2 膠囊
  • 每瓶含量: 30 膠囊
營養成分詳情
  • 推薦使用

    成人每日食用2顆，隨餐食用為佳。

  • 儲存方式

    請保持瓶蓋封閉，避光，儲存於陰涼乾燥處。

  • 注意事項

    如果您正處於妊娠期或者哺乳期, 請諮詢相關醫療保健人員。過敏與甲殼動物的人群可能會出現過敏症狀，若發生請立即停止食用。請置於兒童接觸不到的地方。

有關常見問題或文章，請瀏覽我們的資訊中心 http://help.allysian.com/zh-tw/。

cGMP 在加拿大製造 環保與道德 無人工添加 無人工色素

"優質omega-3 和青蝦素的磷蝦油，快速吸收至細胞膜，更多有效營養。"

重定可能性™

Canada EN 中文
USA EN 中文
Hong Kong EN 中文
Philippines EN 中文
Singapore EN 中文
Malaysia EN 中文
Japan
India EN 中文
Bangladesh EN 中文
Australia EN 中文
New Zealand EN 中文
Taiwan 中文

發送

太平洋時間下午 1:00 之前的訂單會在同一個工作日處理，其餘的時間會在第二個工作日處理。發貨時間在 2 到 5 個工作日之間，具體取決於您的位置。週末或假期的訂單會在下一個工作日處理。訂單一旦發貨，我們將發您一個單獨的追蹤電子郵件，請確保輸入一個電子郵件地址，好讓您可以收到追蹤信息。

零售客戶退貨及交換政策

我們保證客戶對我們所有產品的滿意度，客戶滿意是我們的首要任務。如果您對愛力思科學的產品不滿意，您可以在購買之日起 365 天內將您未開封的產品以原本包裝退回，全額退款或換貨。退貨必須是未經開封及原本包裝。

已開封產品： 愛力思科學為而開封產品提供三十（30）天 100％（百分之百）無條件退款保證。愛力思科學將在購買之日起 30 天內退還或交換已開封和 / 或部分而使用的產品。

退回產品授權編號： 在退回任何產品之前，您必須獲得放置在退貨包上的RMA(退回產品授權)編號。請透過 support@allysian.com 或免費電話 1-844-728-0678 與我們聯絡，我們將在一個工作日內為您提供RMA編號和我們的退貨地址。沒有RMA編號或不正確地址的退貨將不被接受。如果您直接從其他獨立會員購買了愛力思科學產品（不是直接由愛力思科學發貨），而不滿意，則必須將商品退回您的購買地點。

運費： 原本的運費（如果有的話）將不退還，退貨的運費（如果有的話）將會是您支付。然而，給您運送任何交換產品的費用將由愛力思科學負責。請只使用可追蹤的運輸方式運送需要退貨產品，並記下退貨的追蹤號碼。